fuzheng Huayu / Shanghai Sundise - LARVOL DELTA

Fuzheng Huayu Tablets plus Anti-HBV Therapy for Liver Fibrosis or Early Cirrhosis in Patients with Chronic Hepatitis B and Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (ChiCTR) - P=N/A | N=110 | Recruiting | Sponsor: The Third Affiliated Hospital Sun Yat-sen University; The Third Affiliated Hospital Sun Yat-sen University

New trial • Fibrosis • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Metabolic Dysfunction-Associated Steatotic Liver Disease

Fuzheng Huayu tablets reduces the risk of further decompensation after the first decompensation in patients with HBV-related cirrhosis: protocol for a randomized, double-blind, placebo-controlled, multicenter trial. (PubMed, Front Pharmacol) - P=N/A | "This study will be a prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the clinical benefit of Fuzheng Huayu tablets in the risk of further decompensation events in patients with first decompensation. Clinical Trials.gov, study ID NCT07017426; International Traditional Medicine Clinical Trial Registry, registration number ITMCTR2025001365."

Clinical • Journal • Fibrosis • Hepatocellular Cancer • Hepatology • Immunology • Liver Failure • Oncology • Solid Tumor

Development of anticirrhotic drugs from the perspective of the fatty acid metabolism-immune axis: Taking Fuzheng Huayu tablet as an example. (PubMed, Hepatobiliary Pancreat Dis Int) - No abstract available

Journal

Fuzheng Huayu Tablets for Metabolic Dysfunction-Associated Fatty Liver Cirrhosis (Compensated): A Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Study (clinicaltrials.gov) - P4 | N=459 | Not yet recruiting | Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

New P4 trial • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders

Fuzheng Huayu formula attenuates ductular reaction and liver fibrosis potentially through suppressing Gli1 pathway. (PubMed, J Ethnopharmacol) - "FZHY exerts a remarkable antifibrotic effect, which may be mediated by inhibiting the differentiation of HPCs into a ductular phenotype, potentially through suppression of the Gli1 pathway. This finding provides further insight into the mechanism of FZHY and suggests a potential role of Gli1 signaling in its antifibrotic action."

Journal • Fibrosis • Immunology • Liver Cirrhosis • ABCB4 • CK19 • GLI1 • KRT19

Primary prevention in liver cirrhosis patients with esophageal varicesa: a systematic review and network meta-analysis. (PubMed, Front Gastroenterol (Lausanne)) - "For reducing bleeding incidence, the combinations Midodrine + Propranolol (Mido+PPL), Carvedilol + Endoscopic Variceal Band Ligation (Carv+EVBL), and Fuzheng Huayu Capsule + Propranolol (FZHYJN+PPL) were superior...Regarding safety, Mido+PPL, Nadolol (Nado), and Carvedilol (Carv) had fewer general adverse events, while Isosorbide Mononitrate (ISMN), Mido+PPL, and Carv had lower rates of other decompensation events...Carvedilol and Propranolol showed superior net clinical benefit over Nadolol and Timolol. Although Nadolol (alone or with ISMN) may reduce mortality, its higher adverse event rate precludes it as a first-line strategy. FZHYJN, while effective, may increase the risk of other decompensation events."

Journal • Retrospective data • Review • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis

An Observational Study on the Early Intervention Treatment of Fuzheng Huayu Capsule Combined with Antiviral Drugs in High-Risk Populations of HBV-Related Hepatocellular Carcinoma (APASL 2026) - No abstract available

Clinical • Observational data • Hepatitis B • Hepatocellular Cancer • Oncology • Solid Tumor

Fuzheng Huayu formula ameliorates chronic cholestatic liver injury by upregulating PPARa in mice. (PubMed, Chin Med) - "The present study underscores FZHY regulated BAs metabolism and alleviated hepatic inflammation and fibrosis by upregulating PPARa in DDC-induced mice. Our study provides novel insights that FZHY might be a promising drug for chronic cholestatic liver injury."

Journal • Preclinical • Cholestasis • Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Liver Failure • NFKBIA • PPARA

Study on the anti-liver cirrhosis of Fuzheng Huayu tablet : Targeting macrophage PPARα axis-fatty acid metabolic. (PubMed, Phytomedicine) - "FZHY has an anticirrhotic effect, which may promote FAO by targeting the PPARα axis in macrophages and inducing changes in M2 polarization. The above results are expected to provide reliable basic research evidence for the clinical application of FZHY against liver cirrhosis, and offer a potential solution for liver cirrhosis, which currently has no first-line medication recommended by clinical guidelines."

Journal • Fibrosis • Gastroenterology • Hepatology • Immunology • Inflammation • Liver Cirrhosis • GLI2 • PPARA

The CGA combination enhances bile acids alternative biosynthesis pathway and alleviates MASH induced by methionine-choline-deficient diet. (PubMed, J Pharm Pharmacol) - "CGA ameliorates MASH, promoting the hepatic BAs alternative biosynthesis pathway to activate FXR-PPARα restoring FAO."

Journal • Fibrosis • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • ABCB4 • PPARA

Dantao Formula Alleviates Hepatic fibrosis and portal hypertension via Modulation of the cAMP/PKA/ROCK Signaling Pathway in Hepatic Stellate Cells. (PubMed, J Ethnopharmacol) - "DTF alleviates liver fibrosis and PH by regulating the cAMP/PKA/ROCK signaling pathway in activated HSCs."

Journal • Cardiovascular • Fibrosis • Hepatology • Hypertension • Immunology • Liver Cirrhosis • Portal Hypertension • EDNRA

Comparison of the efficacy and action mechanism of Chinese patent medicines for liver fibrosis and cirrhosis. (PubMed, Phytomedicine) - "AHP and LWT are the most effective treatments for liver fibrosis and cirrhosis, respectively according to current network meta-analysis. LWT and AHP may play a role in liver fibrosis and cirrhosis by regulating targets such as STAT3, MMP9, and AKT1, providing a solid foundation for clinical treatment strategies."

Journal • Fibrosis • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • AKT1 • MMP9 • STAT3 • TGFB1

Fuzheng Huayu recipe inhibits alveolar macrophage M2 polarization and oxidative phosphorylation via METTL3-mediated NDUFA2 m6A modification. (PubMed, J Bioenerg Biomembr) - "Moreover, the inhibition of METTL3 suppressed macrophage M2 polarization and oxidative phosphorylation. FZHYR inhibits M2 macrophage polarization through the inhibition of METTL3-mediated m6A modification and downregulation of NDUFA2 and oxidative phosphorylation."

Journal • Immunology • Pulmonary Disease • Respiratory Diseases • IFNG • IGF2BP1 • IL13 • METTL3 • NDUFA2

Role of serum Golgi protein 73 in the assessment of pathological prognosis and its inflammatory influencing factors for hepatitis B virus-related liver fibrosis (PubMed, Zhonghua Gan Zang Bing Za Zhi) - " Two hundred and seventy-eight patients with hepatitis B virus-related liver fibrosis who received entecavir or combined Fuzheng Huayu tablets treatment and completed two liver biopsies (biopsy) in Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine from September 2014 to July 2019 were selected. Serum GP73 levels and ΔGP73 can predict the reversal of fibrosis, with liver inflammation being an important influencing factor following treatment. ΔGP73 combined with ΔLSM can significantly optimize the evaluation efficiency of liver fibrosis reversal."

Journal • Fibrosis • Hepatitis B • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

The Role of Chinese Medicine in the Treatment of Chronic Hepatitis B. (PubMed, Am J Chin Med) - "In contrast, traditional Chinese medicine demonstrates therapeutic advantages in CHB management which are exemplified by Artemisia capillaris, Xiaochaihu Decoction and Fuzheng Huayu Tablet...Future research should employ modern technologies to elucidate these mechanisms further and thus facilitate the development of optimized treatment protocols. Standardized therapeutic approaches derived from such evidence will hold significant clinical value."

Journal • Review • CNS Disorders • Cognitive Disorders • Depression • Diabetes • Hematological Disorders • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Insomnia • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Psychiatry • Sleep Disorder • Thrombocytopenia

FZHYRORDFDHBLC: Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study (clinicaltrials.gov) - P=N/A | N=432 | Not yet recruiting | Sponsor: Zhiyun Yang

New trial • Fibrosis • Gastroenterology • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Investigating the Mechanism of the Fuzheng Huayu Formula in Treating Cirrhosis through Network Pharmacology, Molecular Docking, and Experimental Verification. (PubMed, ACS Omega) - "These findings support Isotanshinone II as a promising compound for cirrhosis targeting the MAPK/NF-κB pathway. Further research is warranted to explore the bioavailability of Isotanshinone II and to optimize its structure for clinical applications."

Journal • Diabetes • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cancer • Liver Cirrhosis • Oncology • Solid Tumor • COL1A1 • MAPK14

Integrated evidence chain-based effectiveness evaluation of traditional Chinese medicines (Eff-iEC): A demonstration study. (PubMed, Acta Pharm Sin B) - "This paper explored its capacity through a demonstration study that evaluated the effectiveness evidence of six commonly used anti-hepatic fibrosis Chinese patent medicines (CPMs), including Biejiajian Pill (BP), Dahuang Zhechong Pill (DZP), Biejia Ruangan Compound (BRC), Fuzheng Huayu Capsule (FHC), Anluo Huaxian Pill (AHP), and Heluo Shugan Capsule (HSC), using both Eff-iEC and the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system...Analysis of community recognition revealed that Eff-iEC more accurately reflects the clinical value of these CPMs, exhibiting superior evaluative capabilities. By breaking through the conventional pattern of TCMs effectiveness evaluation, Eff-iEC offers a novel epistemology that better aligns with the clinical realities and reasoning of TCMs, providing a coherent methodology for clinical decision-making, new drug evaluations, and health policy formulation."

Journal • Fibrosis • Hepatology • Immunology

Histone methylation regulated by EZH2 promotes the formation of liver fibrosis and the inhibitory effect of Fuzheng Huayu Recipe (APASL 2025) - "Compared with the 6-week model group, EZH2 inhibitor GSK343 group and Fuzheng Huayu recipe group significantly decreased the levels of ALT and AST in serum liver function, the content of hydroxyproline in liver tissue, the Sirius red staining area and the gene and protein expression levels of EZH2 and H3K27me3 in liver tissue. Histone methylation regulated by EZH2 promotes the formation of liver fibrosis, and inhibition of histone methylation involved in EZH2 can significantly improve the degree of liver fibrosis in mice. The anti-liver fibrosis effect of Fuzheng Huayu recipe may be related to the inhibition of this link."

Epigenetic controller • Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • EZH2

Mechanisms of Fatty Acid Metabolism in Promoting Hepatocellular Carcinogenesis under the Background of Hepatitis B-Related Cirrhosis (APASL 2025) - "Mice were treated with the Fuzhenghuayu (FZHY) formula and divided into normal, model, and intervention groups... CD36-positive activated HSCs play a role in the development of hepatocellular carcinoma in the context of liver cirrhosis. However, the specific cell types through which CD36-positive activated HSCs primarily induce the occurrence of HCC remain to be further investigated. The FZHY formula may regulate the pre-cancerous microenvironment and inhibit tumorigenesis by suppressing CPT1A expression and reducing CD36-positive activated HSCs."

Fibrosis • Hepatitis B • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Oncology • Solid Tumor • CD36 • CPT1A • SCARB1

Study on the active components of Fuzheng Huayu formal and their anti-fibrotic mechanisms (APASL 2025) - "We further found that Sal B significantly attenuated liver fibrosis in carbon tetrachloride (CCl4)-induced mice, and suppressed erastin- or CCl4-induced hepatocyte ferroptosis in vitro. Sal B, amygdalin, Sin A and C02 are the main ingredients of FZHY against liver fibrosis through protecting hepatocyte from damage, anti-hepatic sinusoidal endothelial cell injury, inhibition of inflammatory response and activation of hepatic stellate cells separately. In addition, ECM1, CDK9, PPARα and cGAS/Sting are the key targets of these ingredients."

Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • ABCB4 • CDK9 • PPARA • SLC7A11

The mechanism of Fuzheng Huayu capsule improves metabolic dysfunction-associated steatohepatitis induced liver fibrosis by regulating ATF3 to inhibit scar-associated (APASL 2025) - "Fuzheng Huayu Capsules have significant effects on anti-MASH induced liver fibrosis in mice, and its mechanism of action may be related to the downregulation of ATF3 expression inhibiting of SAMs. Table and Figure:Figure 1.Schematic diagram showing the mechanism of Fuzheng Huayu capsule inhibiting MASH induced liver fibrosis Figure 2.Workflow of this study"

Fibrosis • Hepatology • Immunology • Inflammation • Liver Cirrhosis • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • ATF3 • CD9 • CSF1R • GPNMB • NOTCH2 • SPP1 • TGFB1 • TNFSF12 • TREM2

Research progress on anti-hepatic fibrosis mechanism of traditional Chinese medicine compound preparation (APASL 2025) - "Fuzheng Huayu Decoction can reduce the recruitment of macrophages in the liver to reduce HSC activation, inhibit NOX-4 and block ROX reaction, regulate the generation and degradation of extracellular matrix to reduce its deposition... Chinese medicine compound preparation can be multi-target, multi-channel anti-fibrosis, and has great potential for anti-hepatic fibrosis."

Fibrosis • Hepatology • Immunology • Infectious Disease • Liver Cancer • Liver Cirrhosis • Oncology • Solid Tumor • MMP1 • TGFB1 • TIMP1

Fuzheng Huayu tablets for treating pulmonary fibrosis in post-COVID-19 patients: a multicenter, randomized, double-blind, placebo-controlled trial. (PubMed, Front Pharmacol) - P2 | "Our previous studies demonstrated that Fuzheng Huayu tablet (FZHY), a traditional Chinese medicine known for its anti-liver fibrotic properties, can improve lung function in patients with chronic obstructive pulmonary disease and attenuate bleomycin-induced pulmonary fibrosis in rats. FZHY attenuates post-COVID-19 pulmonary fibrosis, with good safety profiles. https://clinicaltrials.gov/study/NCT04279197, identifier NCT04279197."

Clinical • Journal • Chronic Obstructive Pulmonary Disease • CNS Disorders • Fibrosis • General Anxiety Disorder • Immunology • Infectious Disease • Inflammation • Mood Disorders • Novel Coronavirus Disease • Pneumonia • Psychiatry • Pulmonary Disease • Respiratory Diseases

Meta-analysis of the efficacy of the Fuzheng Huayu formula in the treatment of hepatitis B-associated liver fibrosis or cirrhosis (PubMed, Zhonghua Gan Zang Bing Za Zhi) - " FZHY can significantly improve the degree of histologic liver inflammation and fibrosis, LSM values, reduce serum liver fibrosis indexes, and serum bilirubin and transaminase levels in patients with hepatitis B-associated liver fibrosis or cirrhosis. Therefore, it is necessary to further explore the optimal course of FZHY and its long-term effects on the risk of complications of cirrhosis such as hepatocellular carcinoma, ascites, and esophageal varicose bleeding, through prospective large-sample multicenter real-world cohort studies."

Clinical • Journal • Retrospective data • Fibrosis • Hepatitis B • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • Oncology • Solid Tumor